GI
AKBA icon

GAMMA Investing’s Akebia Therapeutics AKBA Stock Holding History

GAMMA Investing’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-382
Closed -$531 – 4141
2026
Q1 		$531 Buy
+382
New +$525 ﹤0.01% 3936

Other funds holding AKBA

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
IWN
Independent Wealth Network Urbandale, Iowa $393M AUM 30.08% 1-Year Est. Return
EWS
Eagle Wealth Strategies West Deptford, New Jersey $262M AUM 31.52% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
EF
Entrust Financial Wayne, Pennsylvania $154M AUM

GAMMA Investing's AKBA Position: Q2 2026 in Review

GAMMA Investing sold out of Akebia Therapeutics (AKBA) in Q2 2026, closing a stake of 382 shares — an estimated $531 sold.

GAMMA Investing first reported a position in AKBA in Q1 2026 and held it in 1 quarter. The position peaked at $531 in Q1 2026. 13 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • GAMMA Investing reported no remaining Akebia Therapeutics position as of Q2 2026 after selling out during the quarter.
  • GAMMA Investing sold 382 Akebia Therapeutics shares in Q2 2026, an estimated $531.
  • GAMMA Investing first reported a position in Akebia Therapeutics in Q1 2026 and held it in 1 quarter.
  • GAMMA Investing's Akebia Therapeutics position peaked at $531 in Q1 2026.
  • 13 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.